Philip Morris International Inc. (PM) Earnings Call Transcript & Summary

February 4, 2021

New York Stock Exchange US Consumer Staples Tobacco earnings 78 min

Earnings Call Speaker Segments

Nick Rolli

executive
#1

Good day, and I appreciate everyone taking the time to be with us. We put out a press release earlier today that includes comprehensive details regarding our results for the fourth quarter and the full year of 2020. That release can be found at www.pmi.com. At the conclusion of today's webcast slides — which have also been uploaded to the website — you'll find a glossary of terms, covering the definition of reduced-risk products, or RRPs, along with adjustments, other calculations, reconciliations to the most directly comparable U.S. GAAP measures, and additional heated tobacco unit market data. Except where noted otherwise, whenever we mention IQOS, we're referring to our IQOS heat-not-burn products. Figures shown on a like-for-like basis take into account pro forma 2019 results, adjusted for the deconsolidation of our Canadian subsidiary, Rothmans, Benson & Hedges, Inc., which took effect on March 22, 2019. Be aware as well that growth rates given on an organic basis represent currency-neutral underlying results and like-for-like comparisons, where applicable. This presentation includes forward-looking statements and projections of future results. I'd ask you to review the forward-looking and cautionary statements disclosure included in today's presentation and press release, which provides a full review of the various factors that could cause actual results to differ materially from projections or forward-looking statements. Please also take note of the additional forward-looking and cautionary statements concerning COVID-19. Furthermore, I want to make clear that our remarks and the question-and-answer session today will center on 2020 performance and the 2021 outlook. We intend to discuss the outlook past 2021 at our Virtual Investor Day, happening next week on February 10. At this point, it's my pleasure to welcome Emmanuel Babeau, our Chief Financial Officer; Andre Calantzopoulos, our Chief Executive Officer; and Jacek Olczak, our Chief Operating Officer, who will be joining Emmanuel for the question-and-answer session. Emmanuel?

Emmanuel Babeau

executive
#2

Thanks, Nick, and hello everyone. I trust all of you joining the call are in good health and doing fine. In 2020, our company turned in a solid performance even with the extraordinary difficulties created by the worldwide pandemic. What stood out most was IQOS continuing to expand strongly — it accounted for more than 10% of our shipment volumes and nearly a quarter of net revenues for the entire year. For IQOS users, daily HTU consumption was barely affected by social restrictions, and in spite of considerable limitations, we kept bringing in new users who were moving away from cigarettes at a very healthy rate, reaching 17.6 million in total, with 12.7 million of those having switched to IQOS and quit smoking. Compared with the previous year, HTU shipment volumes rose 28%, and we hit record market shares across major IQOS geographies in Q4. On top of that, 10 markets closed out 2020 with a double-digit national share in December. User acquisition once again proved robust in Q4, driven by our digital commercial model growing more sophisticated and the favorable word-of-mouth generated by our rising prominence, even as restrictions tightened across a number of markets. The biggest pandemic-driven headwinds hit our combustible business, with the heaviest impact felt in Duty Free and Southeast Asia, where Indonesia presented extra difficulties because of the excise tax structure. The EU was the region that suffered least. Although we cannot be sure about when or how long the recovery will take, we anticipate industry volumes bouncing back across the next 1 to 2 years as the pandemic fades. Even with those obstacles, our operating margins once again came in well ahead for both the fourth quarter and the full year; that mirrors the growing weight and profitability of IQOS along with our achievement of the 3-year cost efficiency target 1 year early, which additionally allows us to reinvest in the business. This produced outstanding EPS growth and cash generation, and we surpassed our earlier targets there as well. On the product side, we expanded our smoke-free lineup with a broader selection of consumables, including HEETS Dimension and Fiit, plus the introduction of IQOS VEEV in e-vapor and lil in heat-not-burn. Around the world, we also keep making solid headway in gaining recognition for the beneficial effects of moving smokers to scientifically substantiated RRPs. A key milestone on that front was the FDA's Modified Risk Tobacco Product authorization for a version of IQOS. After that came the premarket authorization of the IQOS 3 device in December. Now to the headline figures. Our net revenue for the full year fell 1.6% on an organic basis. Given the pandemic, that was an exceptionally resilient result; we calculate that Duty Free — after accounting for partial volume recapture in local markets — and Indonesia by themselves were a mid-single-digit drag on our top line growth. Even so, we achieved strong organic growth of 6.9% in net revenue per unit, fueled by IQOS taking up a larger share of our sales mix. On combustible tobacco, pricing rose 3.7%, which mirrors robust pricing across numerous markets, though Indonesia created some counterpressure. If you set Indonesia aside, combustible pricing stood at roughly 6%. Even with organic net revenue and combustible volumes falling, our adjusted operating income margin on an organic basis climbed 240 basis points. That speaks to how IQOS lifts both our gross margin and the SG&A-to-net-revenue ratio, a topic I'll revisit. Adjusted diluted organic EPS growth came in at 7%, beating the roughly 6% we had guided and signaling a robust close to the year in Japan. That leads into Q4, where dynamics closely mirrored the full year. Organic net revenue fell 3.5% — a big step up from Q2's drop of nearly 10% — as persistent softness in Indonesia and Duty Free plus a smaller total market in the Philippines, price increase effect included, outweighed IQOS's strong showing. Net revenue per unit rose a solid 5.2% once more, on the same drivers as the full year. Adjusted operating income margin grew 200 basis points, producing adjusted diluted EPS growth of 7.4%, all organic. Before returning to the full year, let me unpack the robust underlying Q4 dynamics a bit further. HTU shipment volumes kept climbing strongly, hitting a record 21.7 billion units, powered by the EU region, Japan and Russia. In Japan, industry was soft, as anticipated, since consumer and trade deloading after October's tax-driven price hike caused a 13% drop in the total tobacco market, cigarillos included. We greatly outpaced that trend, as a powerful IQOS offtake and share finish pushed shipments higher both for in-quarter sellout and to build suitable inventory for an expected strong start to 2021. As social restrictions began tightening late in the quarter across a number of markets responding to a second pandemic wave, combustible volumes and revenue took a hit from lower mobility and social occasion, though far less than in Q2. Even so, IQOS's strength let the EU, Eastern Europe and East Asia and Australia region post mid-single-digit top line growth. Beyond that, ongoing difficulties in Indonesia and Duty Free against a hard comparison, plus a smaller total market in the Philippines right after a price increase, held back revenue growth. With restrictions still in place across many markets in Q1 2021 and a difficult prior year comparison, we anticipate improved top line performance, which I'll address later. Now let me dig into what drove our 2020 margin expansion, beginning with gross margin, up 200 basis points organic, powered by several levers. To start, the transformation we've been carrying out keeps raising the proportion of IQOS consumables within our business. The second element is combustible pricing. The third element is the attention we pay to productivity across manufacturing and the supply chain as a whole, which offset a decline in combustible volume — made worse by the pandemic's effects — along with inflation, investment and exceptional COVID-driven expense within our supply chain. Our emphasis on SG&A efficiency added to gross margin growth, since on an organic basis our adjusted marketing, administration and research costs came in 40 basis points lower measured as a share of net revenue. That mirrors the continuing digitalization and simplification of how we run the business, among them our IQOS commercial engine and more efficient working methods. Keeping a sharp eye on cost efficiency lets us lift profitability even as we keep putting money into IQOS growth. It gives me real pleasure to say that the 2019, 2021 goal of more than $1 billion in annualized gross savings has already been reached in just 2 years, and $1.1 billion of that had been delivered by the close of 2020. Manufacturing and supply chain productivity plus device costs produced over 2/3 of those savings, since our attention to efficiency, quality and footprint more than offset inflation, supply chain investment, exceptional COVID-related costs and the impact of reduced combustible volumes. Commercial efficiency and G&A cost accounted for what was left.

Emmanuel Babeau

executive
#3

What matters here is that these cost reductions exclude anything tied to the pandemic, for instance less business travel and the forced migration of buyers toward online and digital purchasing. When you combine elevated production expenses with SG&A reductions of this kind, our estimate of the net efficiency gain attributable to the COVID effect comes to roughly $150 million; we intend to provide more detail on our cost program and on accelerating IQOS growth during next week's Investor Day. Thanks to the substantial rise in our profitability and outstanding earnings growth, we generated close to $10 billion of operating cash flow across the year, comfortably exceeding our projection of no less than $9 billion. That figure equates to 3.5% growth on a like-for-like basis excluding currency, and it likewise captures the benefits of continuing working capital programs — a remarkable result given a year marked by major disruption to worldwide supply chains. Our capital expenditures came in at $0.6 billion, which is under our historical run rate. Meaningful gains in manufacturing efficiency have led to reduced ongoing needs; even so, we also gained from the timing of particular investments, and we anticipate CapEx of approximately $0.8 billion during 2021. Beyond putting money back into the business, returning cash to shareholders is the main use of our funds, and this year we increased the quarterly dividend to an annualized level of $4.80 per share. Capital allocation is another subject we plan to address at Investor Day. Now let me move to industry volumes, which fell roughly 6% during 2020, leaving out the U.S. and China. That contrasts with the historical norm of a 2% to 3% decrease; in our estimation, the 3% to 4% gap can be attributed almost completely to how the COVID pandemic affected the combustible category. As our results make clear, the smoke-free segment has shown extraordinary resilience, which speaks to its convenience and its fit for a range of use occasions. As we've discussed in earlier quarters, the decline in daily combustible consumption stems from 2 principal causes. The first is fewer usage occasions while people were confined, particularly in markets with many daily wage workers; the second is a smaller number of social occasions because hospitality venues closed and gatherings were restricted. Duty Free is still weak as well, tracking worldwide travel; daily consumption has partially bounced back from the worst stretch of limited mobility in Q2, and we anticipate steady improvement as the pandemic fades. Everyone recognizes that substantial uncertainty persists regarding how quickly, in what form, and when we exit the pandemic; and right now, serious resurgences in infections are occurring across many countries. Still, drawing on what we recently observed under renewed lockdown conditions, we don't anticipate another severe consumption plunge like the one in Q2 2020; even so, whether any rebound materializes this year is unclear, so we take the historical average decline of 2% to 3% as the floor for industry trends during 2021. I'll revisit this point when we get to guidance assumptions. Let me now turn to how we performed on volume. Soft combustible industry volumes took a hit, and that was made worse by where we're exposed — Indonesia, Duty Free — plus the fact that our premium portfolio leans too heavily on occasions tied to social consumption. So it stands to reason that once the pandemic fades, we ought to see improved momentum in market share, and I'll get to that in a moment. Inventory swings quarter to quarter, as anticipated, washed out across the year, and there wasn't any meaningful gap between our IMS and our shipments. The standout on the volume side was clearly the 76.1 billion HTUs we shipped during 2020; that landed slightly above the top of the 75 billion to 76 billion range we'd previously guided and works out to 28% growth versus the year before. HTU net revenues rose by 33% organically, which partly reflects a favorable mix. We're still firmly on course to hit our 90 billion to 100 billion unit target for this year, and next week we'll share more about what we see beyond 2021. Thanks to this robust IQOS performance, heated tobacco units accounted for more than 10% of total shipment volume in 2020 and more than 12% during the fourth quarter, versus roughly 8% in 2019 and 5% in 2018. We still anticipate that this share will climb over time as IQOS keeps building positive momentum, serving as a strong engine for both revenue and margin expansion. Our sales mix is shifting quickly. Smoke-free products represented 26% of total net revenue in Q4. IQOS devices were about 7% of the $6.8 billion in RRP net revenue for the full year, largely because of a naturally lower ratio of new users to existing ones, a longer replacement cycle, and geographic mix. In certain geographies, we continue to sell a sizable quantity of the cheaper original IQOS 2.4+ device, and we've now rolled out lil Solid in Eastern Europe. Turning to our total international market share. Our volume share rose 0.2 points before accounting for the effect of Duty Free cigarettes and Indonesia; the driver was a higher share for heated tobacco units, up 0.8 points to 3%, with only partial offset from a lower cigarette share; in key markets where IQOS has a meaningful presence, our share grew with very few exceptions. That said, Duty Free and Indonesia dragged down our total international market share. Marlboro is still easily the top brand globally, holding 9.5% share of cigarettes in 2020. But in many markets it over-indexes to occasions involving social consumption, which are naturally reduced while COVID-related restrictions are in place. Sure enough, we observed aggregate Marlboro share movement following pandemic developments throughout the year and expect its recovery to track similarly. On value share — meaning our share of total industry net revenue, excluding the U.S. and China, which ties more closely to financial performance — we estimate we're considerably above our volume share, reflecting the premium positioning of Marlboro and IQOS. For 2021, we anticipate a robust expansion of our value share, with IQOS serving as the main engine. Now, let me move on to Indonesia. Following a challenging 2020, as we go into 2021 our share pattern is sequentially steady, buoyed by the fact that we lead the hand-rolled kretek category, which has resumed growth. On February 1, new excise duty rates take effect, and across 2021 our portfolio will see a weighted average rise of approximately 13%. That figure is roughly consistent with the typical yearly rise seen before 2020, and because we are over-indexed toward hand-rolled kreteks, where excise rates have not changed, PMI faces a below-average increase for the industry. Since these higher-margin segments—which sustain substantial employment in Indonesia—carry both a lower price and less tax than machine-made product, we foresee a tailwind for our market share and our financial results in the year ahead. Notwithstanding the harm done to government revenues, no meaningful step has yet been taken to equalize conditions between the Tier 1 and below Tier 1 segments. We continue to hope the government will eventually tackle this matter; regarding the minimum retail selling price, enforcement has kept advancing only gradually because of mobility restrictions. Even so, we believe the market impact is probably going to be smaller now. The vast bulk of the industry currently sits above the minimum level.

Emmanuel Babeau

executive
#4

And since the minimum price stayed the same in 2021, passing along the new excise rate will lift the rest of the industry past compliance thresholds. We likewise observed that growth in the below Tier 1 segment flattened during the fourth quarter, along with a steady uptick in our shipment volume. As has happened in numerous other markets, daily consumption has risen since Q2, yet it remains under pre-pandemic levels and stays vulnerable to social restriction. Indonesia weighed heavily on our 2020 financial results. Although plenty of work lies ahead on the excise structure and uncertainty tied to the pandemic persists, for 2021 we anticipate a far less negative industry volume trend, an improved market share outlook and a considerably smaller hit to our overall performance. Across the entire international cigarette category, we project a rebound during 2021 and 2022 as COVID's negative effect on daily consumption unwinds. The category's fundamentals also stayed sound, among them price elasticity, which we put at roughly minus 0.4 on a global average basis. Turning to our combustible portfolio, investment levels are still sufficient. That said, somewhat more could be required right after COVID; we will keep investing in Marlboro's brand equity, still by far the world's leading brand. In light of the economic environment, managing price gaps and expanding our share of the low-price segment will also be priorities. Pricing within combustibles stays a key performance driver. And although COVID's carryover effect may influence our 2021 variance, our portfolio's pricing power stays strong. Furthermore, as HTU volumes rise, that pricing power grows thanks to higher price productivity on HEETS and our other HTU brands. I would also point out that pricing is no longer the only driver of our top line growth, since IQOS's growing weight in our sales mix produces significant growth in our average selling price. I now turn to IQOS performance. We estimate 17.6 million legal-aged IQOS user as of December 31; that amounts to roughly 1.2 million adult users added since the end of the third quarter and over 4 million in 2020. Notably, user acquisition sped up through the year's second half, even with renewed pandemic-linked restriction in the fourth quarter across a number of markets. Our accelerated pivot to digital and remote engagement, paired with strong momentum for the IQOS brand, is paying off; we further estimate that 72% of this total, or 12.7 million active smoker, have switched to IQOS and stopped smoking, with the balance at various stages of conversion. This once more reflects widespread user growth momentum across all IQOS geographies, including the EU region, Japan and Russia. As our user base expands in markets such as Japan and Russia, we are increasingly enriching our offer and segmenting the category with new products and more price points. Bringing lil SOLID to Russia and Ukraine during the back half of the year allowed us to connect with a wider group of legal-age smokers there and draw them toward the smoke-free segment. Even so, this is still an early phase, and the count of users we gained via lil device purchases is not material relative to our overall user base. We've mentioned before that additional exciting IQOS innovation is slated to arrive over the next several quarters, and we'll share more detail on that next week. Turning to the EU region, HEETS captured a record 5% of combined cigarette and HTU industry volume in the fourth quarter. This slide illustrates that this mirrors robust sequential as well as year-over-year expansion in IMS volumes. Please note the difference between the steady sequential rise in IMS and how sequential quarterly share moves, since the latter can be skewed by seasonality in the combustible market, along with other pandemic-related swings like border closures and other social restrictions. Consequently, 2021 and the years beyond will probably also deliver underlying share gain, more pronounced during winter months, with a converging pattern in Q2 and Q4. This outstanding result mirrors robust expansion in Italy, which closed the year at 10% share, with the vast bulk of user acquisition arriving organically, as rising awareness and the product's growing prominence generate its own momentum. Germany and Poland contributed strongly as well; we gained an additional 0.6 million IQOS users during the fourth quarter, bringing the total to 5.2 million, extending the recent strong trend. Beyond that, we made further headway in Spain and in the U.K., where National and London HEETS offtake shares both kept climbing, with the London figure hitting nearly 4% for the quarter; the select key cities shown here illustrate IQOS's strong traction and the superb potential for national shares throughout the region. I'd also point you to the appendix, where we present shares for key EU markets and key cities worldwide. Russia also maintained strong momentum, with our HTU share climbing 2.2 points to a record 7.2% in Q4. Just as in the EU region, we call attention to how seasonality in the combustible category affects quarterly shares. Seasonal swings in Russia can be sizable, and we encourage you to keep that in mind as you read our quarterly results going forward. One standout achievement later in the year was broadening our product lineup with lil SOLID and the Fiit consumable, serving a wider array of adult smokers spanning the socioeconomic spectrum. Across both Russia and Ukraine, most consumers who buy a lil device are new users, and this incrementality helped speed up user acquisition, with a high conversion level consistent with IQOS. The quantity of Fiit consumable sold is roughly proportionate to lil device ownership. And during this initial phase of commercialization, within the context of the IQOS business in this market, the two are both small. Still, although we've effectively moved a large number of legal-aged smokers in the medium price segment over to IQOS, this is a positive sign for our capacity to connect with consumers in particular markets in the medium and below price segment, for whom buying power might block them from joining the category. The IQOS brand likewise has a strong pull throughout the Eastern Europe region. Swift expansion and outstanding market share demonstrate our nimble commercial approach and consumers' hunger for smoke-free alternatives, even in markets where purchasing power is lower and, once more, act as highly encouraging signs for the ongoing advance of our national market share. In Japan, our total reported share for heated tobacco units hit 22.1% during the fourth quarter, buoyed by line extensions for both Marlboro HeatSticks and HEETS, including the recent introduction of Marlboro Black Menthol. On a more representative total tobacco basis, with cigarillos included and adjusted for trade inventory movement, our HTU brands' share rose 2.9 points compared with the prior year quarter and 1.2 points sequentially, reaching 20%. Following the October price increase, both HEETS and Marlboro HeatSticks gained market share, underscoring the strength of our price tier portfolio.

Emmanuel Babeau

executive
#5

We're particularly happy with the offtake share we saw in Tokyo during Q4, since it hit the 25% mark in December. For our HTU brands, adjusted in-market sales volume in Q4 2020 rose 0.6% versus the prior quarter, and we see that as a solid result considering how much consumer offtake got pulled into Q3 ahead of the price increase. Heated tobacco as a whole accounted for more than 27% of the entire tobacco market during Q4, and IQOS held onto its large portion of that segment. We're particularly happy with the offtake share we saw in Tokyo during Q4, since it hit the 25% mark in December. Much the same pattern shows up in major Japanese cities, Sendai included. In Korea, the market faces particular difficulties tied to consumers misunderstanding the category. Even as we keep working on that problem, it's worth noting that Kuala Lumpur in Malaysia has now moved ahead of Seoul when it comes to market share, passing into double digits during the third quarter; on top of solid gains in markets where we already operate, IQOS keeps expanding geographically. We draw on our digital strengths to enter 3 additional markets: Estonia, Kuwait and the Maldives. That brings to 64 the total count of markets where IQOS can be purchased, and more than half of those sit outside the OECD; we're carrying on with commercialization of IQOS VEEV, our new e-vapor product, starting with the first EU launch in the Czech Republic in December. That comes after lead market New Zealand in August 2020, and we'll keep moving into new markets across 2021, among them Italy and Finland in the next few weeks. As we've noted before, IQOS's commercial infrastructure lets us deploy efficiently and at scale. The VEEV device and the consumable will both carry a premium position; we also put a lot of weight on efforts to prevent youth access across all our products. While rolling out IQOS VEEV, we'll be trialing age verification technology in chosen markets. Turning to sustainability, I want to stress once more that our corporate strategy and our sustainability strategy line up closely. ESG matters are business matters that feed into our long-term strategy and rest at the heart of our mission. Even with the unmatched difficulties brought by the global pandemic, we haven't wavered in working to become a more sustainable company, and we hit several important milestones during 2020. By swapping cigarettes for a less harmful alternative, we can meaningfully cut the negative effect our product has on consumer health; that's the reason the heart of our strategy centers on tackling the impact of P, product, the first and most essential pillar in how we approach sustainability. This is what sets our company apart and underscores our distinctive value proposition as the last piece of our ESG + P framework. Retiring cigarettes stays our priority. And during 2020, we estimate another 4.1 million legal-aged smokers joined the smoke-free category with IQOS, bringing the total to 12.7 million who have now switched and quit smoking. We're also highlighting a few recent standout accomplishments in ESG here, and we'll dive into those further at Investor Day. There's still plenty left to accomplish, but we feel that the way we handle sustainability, materiality, and disclosure—openly and thoroughly—positions PMI as a strong model of impact. We get there by deliberately weaving sustainability into how we operate and by treating it as a chance to innovate and expand, including the leading part we play in tobacco harm reduction. Put differently, what we're going through is a sustainability narrative unlike any other, and that's another subject we'll pick up again next week. Now let me move to our 2021 guidance, and there we're anticipating a substantial rebound. What's largely unclear is how quickly and in what manner the world emerges from the pandemic. COVID certainly threw our 2020 results off course, and it isn't finished yet, so this uncertainty has to be built into what we expect for the year ahead. Given that vaccine distribution has only just begun and lockdowns remain active in numerous markets, we're not counting on anything substantial shifting during the first quarter, which also brings an unfavorable comparison against the pre-COVID prior year. Past that point, outcomes could obviously vary widely, and we're accounting for that by giving a range for the organic growth we assume in net revenue and EPS. Even if restrictions drag on, these ranges presume we won't drop back to the weak consumption seen in Q2 2020, which matches what we observed when the second wave hit with less severity. When it comes to Duty Free, any bounce in worldwide travel will probably trail improvements in mobility within individual countries. Our guidance bakes in no real rebound for Duty Free during this year. Even with that assumption, we're looking for organic net revenue growth between 4% and 7%, along with organic adjusted diluted EPS growth of plus 9% to plus 11%, or plus 14% to plus 16% when measured in dollars; the narrower EPS range mirrors the possibility of heavier growth investment should recovery arrive faster. So our assumption calls for at least 150 basis points of margin expansion under every scenario inside that range. That captures the continuing favorable mix from IQOS in our portfolio plus the benefit of cost savings, net of sustained growth investment. This anticipated organic EPS growth, which includes an estimated favorable currency effect of roughly $0.25 at prevailing rates, works out to an adjusted diluted EPS range of $5.90 to $6; no share repurchases are assumed in this guidance. The guidance further presumes we hit our 3-year HTU shipment volume target of 90 billion to 100 billion units. Turning to a few other key assumptions behind this guidance, we anticipate total industry volume moving between flat and minus 3%, contingent on how quickly and in what form the pandemic recovery unfolds. We expect to beat the industry trend thanks to IQOS share gains, producing a PMI volume forecast of plus 1% to minus 2%. There's also a manageable excise picture here, with a favorable structural shift in Turkey, an above-average rise in Russia, and an increase in Indonesia that matches historic averages. Our combustible pricing power, as I noted before, is still strong. Still, because of the carryover effect from 2020, particularly in Indonesia, and the near-term fallout from the COVID crisis, we're assuming combustible pricing of 2% to 3% in 2021, or roughly plus 4% if you exclude Indonesia. Just like in 2020, the largest contributor to top line growth will probably be a heavier weighting of the IQOS business, which brings significantly higher average net revenue per unit. Per this morning's press release, we assume a full year effective tax rate of about 22%, and we assume operating cash flow will climb sharply to roughly $11 billion at prevailing exchange rate, subject to capital — to working capital requirement. Capital expenditure, as I said, is assumed at about $0.8 billion. Now let me take a moment on what we expect for the first quarter.

Emmanuel Babeau

executive
#6

We expect our organic net revenue to be roughly flat to a bit lower, since we're up against a tough Q1 2020 comparison. That quarter gained from inventory stockpiling in March, when the pandemic started spreading across many markets, and it was also largely free of COVID. This outlook includes ongoing robust year-over-year gains in HTU shipment and IMS volumes. Given typical seasonal trends and fewer selling days in Q1, we anticipate those volumes will be about flat to modestly under Q4 2020 on a sequential basis. We likewise anticipate solid sequential HTU share improvement versus Q4 on both an underlying and reported basis, keeping in mind the seasonal element in the combustible market that I noted earlier; we look for solid margin improvement in Q1, driven mainly by the favorable mix from IQOS plus the cost savings achieved during 2020. We think that translates into organic adjusted diluted EPS growth near 8%, roughly $1.40, and that figure includes an estimated $0.09 tailwind from currency at prevailing rates. Turning past the first quarter, nobody will be shocked that the simpler comparison in Q2 ought to allow above-average year-over-year expansion in volumes and net revenues. In summary, we outperformed expectations, delivering plus 7% organic EPS growth amid the turmoil of 2020. Through IQOS, we're building a business that will produce superior, sustainable growth in the years ahead. IQOS's ongoing momentum despite the pandemic's difficulties shows this structural growth trait. We're equally dedicated to preserving the robust leadership and competitive strength of our combustible business. Several levers can drive our top and bottom line. First is IQOS's potent mix effect. Second is pricing, which stays vital for combustible and, when suitable, for RRPs. Beyond that, efficiency across our manufacturing, supply chain and SG&A expenses is another lever as we keep refining our business model. What's more, with the IQOS VEEV and lil launches, we're widening and elevating our product range and innovation during 2021. You should also expect us to deliver additional exciting innovation for our IQOS heat-not-burn platform. As I said, sustainability sits at the core of our smoke-free strategy, and we keep striving relentlessly to advance our mission. Our organization showed remarkable resilience in 2020, managing and expanding impressively through one of the hardest stretches in recent memory. Simultaneously, our business kept transforming, absorbing and applying new skills and capabilities. In brief, we're confident about what's ahead, and we'll go deeper on this subject at our Virtual Investor Day on February 10; we hope to see you there. Thank you. Andre, Jacek and I would now be glad to take your questions.

Bonnie Herzog

analyst
#7

Congrats to you both, Andre and Jacek. My opening question is about margins. Emmanuel, I'd like you to expand a bit on what you expect for margins — specifically, any positive fixed cost absorption you anticipate as the investment behind IQOS gets amortized across a volume base that keeps getting larger and growing faster. And while I'm on that, given that your variable costs are declining, which you mentioned, and the strides you've made with digital, could you discuss that too, plus how significant an effect or how large an opportunity this might represent going forward?

Emmanuel Babeau

executive
#8

Absolutely, Bonnie. Glad to. This will just be a small preview compared with what's coming next week. So please be patient with us, and we'll go into far greater detail then; still, I can definitely give you a few headlines about what we'll present next week. What stands out in our 2020 figures, I believe, is that alongside IQOS's excellent performance, we've also leveraged cost efficiency as a strong tool for driving results. That comes through very plainly in our numbers. So the full savings of at least $1 billion, which should have taken 3 years, are being delivered by us in 2. And the nice part is that our cost efficiency efforts span multiple levels, and a lot of those, naturally, tie to IQOS, though for some of them IQOS isn't the only area involved. Looking at gross margin, it's fairly clear that we're achieving real success in manufacturing productivity, which is a strong engine for additional margin gains. There, we're pursuing margin improvement across the entire portfolio on a global basis; so it isn't limited to IQOS, even though IQOS, being a business with less maturity, likely offers us more runway, so to speak, for boosting productivity. We're definitely making excellent progress on that front, yet we're also driving manufacturing productivity on CC. Then, regarding SG&A, I believe you can spot 2 cost efficiency drivers. The first, I'd say, is probably something you'd encounter at plenty of companies right now. We're striving to become a more efficient and agile organization; so we're pushing to be more digitized, we're simplifying our ways of working, we automate, we standardize — and that lets us avoid being a cost cutter, instead simply removing cost so we become a better company and deliver stronger performance overall. And then there are factors genuinely tied to our commercial performance, and not solely to IQOS, though mostly to IQOS, and there are 2 of them. The first is all the investment we've made previously, which is a terrific platform on IQOS. So I'm not claiming we've finished putting money into this—we'll carry on with that spending. Naturally, though, what we have at this point is an outlay being amortized across a rapidly expanding customer base; meanwhile, the pace at which we're raising that spending isn't matching how quickly IQOS is growing; and on top of that, there's the excellent work we're delivering. That's possible because of digital, and also because of everything we keep learning within the IQOS business, where we managed a really solid reduction in every variable cost per user. Still, I'll leave it at that, since we'll go into more detail on this next week.

Bonnie Herzog

analyst
#9

All right, that was quite useful, and I'm grateful for it. Moving on to my next question: given all the headway you've achieved with IQOS in expanding the user base, which is now so big, when you look ahead, could you discuss how you might further segment markets using your various platforms, or perhaps different price tiers, as you keep converting additional smokers? You did mention this briefly. I suspect you'll say more about it the following week. Still, when I examine your business, it suggests that to reach your aspirational goal of 250 billion units by 2025, your user base will likely have to double within roughly the next 3-plus years, according to our analysis. So I'd be glad to hear any approach or observations on that front, since if I consider it, I presume a greater share of the conversion will come from other reduced-risk technologies. And how do you expect your mix to shift as time goes on?

André Calantzopoulos

executive
#10

Yes. I'll take the first crack at it. I remain convinced, Bonnie, that across the coming 3 years, as I've stated on numerous occasions, heated tobacco technology will dominate, since it possesses the greatest capacity when it comes to taste and satisfaction for converting individuals; regarding segmentation now, in my view, most markets will require 1 or 2 heat-not-burn technologies, if I keep to this segment, and likely 2 to 3 as time passes, across consumable price segments, allowing us to reach the overwhelming majority of the market. There will be exceptions where covering 4 price segments with likely 2 technologies becomes necessary. And next week we'll discuss the upcoming technological advance for aerosolization in heat-not-burn, which will tackle numerous pain points consumers experience at present. Now, it's clear the heated tobacco product constitutes a single category. In my opinion, that's the quickest expansion, in terms of revenue as well as bottom line and volume. The second is plainly e-vapor; we're moving into this market since I think consumers exist there who wish to switch trade to such products. There are many dual users, and we also observe dual users of heat-not-burn alongside e-vapor whom, naturally, we'd like to capture. I think we can additionally capture consumers for other e-vapor products. The crucial thing there is plainly to capitalize on the infrastructure and the brand name of IQOS. My view is that this product is quite strong, and that's the immediate feedback we receive, yet we have to establish equity since that's an issue for the category, as you're aware, plus consumer loyalty, because for e-vapor economics to be optimal, a premium position alone isn't enough — you also need buyers who stay loyal. If you simply cut prices on products and move them, and then someone owns 10 separate items from 10 separate rivals and uses half a cartridge of yours each week, turning a profit becomes very hard and, even more crucially, sustaining an infrastructure becomes very hard; right now we benefit from having substantial infrastructure through IQOS that we can draw on. Within the RRP, IQOS equity is unquestionably the strongest, so I believe that helps. The technology is solid. Since we're premium, I think we can gain ground in this category; and then clearly, over time we also intended to broaden into pure nicotine offerings such as nicotine pouches or the P3, though I consider those more occasional-use items or non-predominant-use items. So that's a bit — and once more, apologies for stopping here, but we'll expand on this further — much more — thoroughly next week, okay?

Michael Lavery

analyst
#11

I'd like to revisit IQOS. In the Philippines, your share sits at 20 basis points — obviously a modest figure, yet it's still quite early in that market. From what I gather, you entered that country with no stores at the outset. On this call, you also brought up certain digital rollouts in Estonia, Kuwait, and the Maldives. So I'd appreciate gaining a bit more insight into how those digital approaches function. And clearly, as seen in the Philippines, they're poised to become effective rather fast. Could you flesh out a bit how you're approaching that market?

Jacek Olczak

executive
#12

Sure. This is Jacek speaking; indeed, our Philippine start came this year — to be exact, within Manila, not even encompassing greater Manila; and the product, as we anticipated, in fact performed quite nicely; this ranked among the earliest launches conducted entirely digitally, if I can put it that way, which also stemmed from needing to pivot our approach at the last minute because of COVID restrictions and the overall COVID effect. And the product is beginning to gain solid momentum. I believe we'll remain in Manila for some time yet, which is, honestly, no big secret since we're pursuing an identical course of the same playbook for expansion across all markets, correct, particularly when you enter a sizable market such as the Philippines. Still, the product has been warmly received. In my view, the flavor profile and so forth align quite well. We're additionally trialing various route-to-consumer frameworks, as we do when arriving in countries where you have a stick purchase. A great deal of consumption happens on trade instead of merely off trade; thus we must devise really strong solutions for that; however, I feel quite optimistic about that portion of Asia, which remains uncharted territory for IQOS.

Michael Lavery

analyst
#13

All right, that's useful. And then a second item regarding buybacks. It's useful to have it clear that the guidance doesn't factor that in at all. Still, given that we now have some favorable currency movements and the balance sheet sits where it does, it really looks as though that might be — it could become relevant. Could you share what conditions you'd require in place or what you'd want to observe before you'd consider restarting buybacks?

Emmanuel Babeau

executive
#14

Well, if you can wait with us until next week, we'll be doing a comprehensive look at how we allocate capital, and at that point we'll cover every element.

Michael Lavery

analyst
#15

All right, that's fine. Maybe I can just replace that question instead. Is there any way you could share where things stand regarding Platform 2 and TEEPS? Do you have anything new on that?

Jacek Olczak

executive
#16

Regarding TEEPS on Platform 2, what I'd say is that we're going to keep moving forward with it, and this time the commercial market test will take place this year, in 2021.

Vivien Azer

analyst
#17

I also wanted to dig deeper into IQOS. Could you provide some insight into how the consumables mix breaks down between traditional tobacco flavors and the newer flavors you currently offer in the market?

Jacek Olczak

executive
#18

This is Jacek speaking, Vivien. It differs from one market to another, alright? As you're aware, we do offer menthol flavors. We have additional flavors as well. Even so, IQOS, to be honest, in the majority of locations derives its appeal largely from tobacco flavors. Ultimately, most of the segments we're going after right now, where we're running at scale, most of those segments fall into the flavor — tobacco flavor category, correct? So IQOS truly offers a very strong proposition. It also delivers an excellent proposition in menthol and other flavors. So that shifts depending on the country, and you really can't — I believe if I were to give you the global share of flavors, it would simply be misleading. The average doesn't capture that. But it generally tracks, if you're in a market where menthol dominates like Japan, menthol's dominance, whereas if you're mostly in full — meaning cigarette markets without menthol, then you're mostly there. Occasionally it's somewhat over-indexed in menthol overall since it carries a bit more impact for people, making it easier to switch.

Vivien Azer

analyst
#19

Got it. And for my second question, also about IQOS — regarding how market share moved in Japan, whether during the quarter or across the year, could you give some context on how much came from Marlboro versus HEETS?

Jacek Olczak

executive
#20

Marlboro remains the biggest source of our total volumes and of the growth, so we're quite happy that over the past year we kept growing Marlboro. Clearly, HEETS, priced no lower than Marlboro, showed somewhat stronger momentum than Marlboro, yet both are in fact driving the growth. And it's quite interesting, Vivien, that you ask, since this is the first market where we attempted the dual — or double — dual positioning of the consumables, Marlboro and HEETS in Japan. As you're well aware, we also rolled HEETS out in a few Eastern European geographies, in Russia. First, we introduced the above premium propositions to HEETS, the HEETS Creations; and the HEETS Creations contributes; so we favor pushing premium even higher for HEETS in Russia. And HEETS Creations in Moscow now make up roughly 10% of total HEETS volume; so that's quite good. And afterward we filled in the notch below price segment by launching the lil Fiit proposition. So now in Russia, we're testing whether IQOS can operate in the free essentially price segments on the devices. And the spread is pretty phenomenal because IQOS devices range from $60 on the premium device, and then we drop to $20 on the lil device. And then we have coverage on the consumables ranging from RUB 170 per pack to RUB 130; so it gives you a hint how broadly we now — why — we can go with IQOS reaching the segments above medium and below medium. And this is despite, as you know, that we face competition in Russia; but honestly, competition when it comes to the devices is basically near 0; so it's a bit of very aggressive promotions, but we keep delivering strong growth on IQOS, both in user acquisitions measured by the device sales and by the HEETS — further expansions on the HEETS. And what's also good in places like Russia is that we keep growing in the top cities, which we began a few years ago; so we have continuous growth in the cities, and the expansion doesn't need from that growth which we have in Moscow, St. Petersburg and the other main cities.

Gaurav Jain

analyst
#21

Regarding the organic margin gain, you're guiding to 150 basis points for FY '21, and that comes after a 240 basis point lift in FY '20. That year benefited from things such as production and travel costs, a German VAT reduction, and so on. What I'm getting at is whether your true underlying margin gain is nearer 200 basis points rather than 150, and whether that's plainly driven by IQOS. Should we view the coming years that way too?

Emmanuel Babeau

executive
#22

For the medium term, we'll say more about the outlook next week. As for this year, Gaurav, I'll leave your assumption to you. I believe it's evident which one-off savings arose from COVID, so you're able to put that into your model. And I think it's also evident what drives margin gains: the favorable effect of IQOS growth on per stick revenue, on margin, plus all the cost efficiency work. That is genuinely the force behind — that has powered the margin gain in 2020, and it will keep doing so in 2021. Naturally, past 2021 as well, though we'll say more next week.

Gaurav Jain

analyst
#23

Alright. My follow-up concerns the European Beating Cancer Plan, unveiled at the start of this week, and they mention items such as a flavor prohibition, plain packaging, and raising levies on heated tobacco so they match those on cigarettes. So what's your take on that? And in what way do you factor these kinds of risks into your outlook?

André Calantzopoulos

executive
#24

Okay. To begin with, it's a plan, and in my opinion there are numerous favorable elements in it too. Above all, we aren't discussing taxes. What I mean is, this falls under directives. The tobacco excise directive, which controls the excise tax, and the tobacco product directive, which is the product regulation, right? Currently the first, the tobacco side directive, doesn't provide for a reduced risk product category, so it must be revised no matter what, okay? And we're not discussing hikes. What it does is establish a framework within which member states are able to tax. Our position is that the lack of combustion, for instance, is a crucial criterion for taxing cigarettes differently from other products. And after that, within that significant divide of change in toxicity and exposure, member states are permitted to set varying tax rates for these products. Yet this product ought not to be, in any way, more expensive than any combustible category on the market, okay, as a minimum criterion; but this needs to take place. Nobody stated that taxes would rise or strike tobacco products, honestly, at this point or on vapor products, okay? So all of this remains to be determined, and the talks will begin during this year and go on into next year, regardless. So that's regarding — and then the tobacco product directive has been served, I hope there will be somewhat greater regulatory clarity in it concerning RRPs because — and e-vapor products because right now, we've left it to the member state to regulate, which, honestly, isn't harmonizing a directive, first; and second, it's a headache for every industry participant since each country has its own distinct regulation. And we have consistently supported rigorous regulation of these products, as long as it's differentiated from cigarettes, okay? Now some voices argue that these products ought to be identical to cigarettes; but ultimately, it was quite clear in the cancer plan as well that all — in the Q&A that only on the basis of science and evidence will they make decisions. So at this point I wouldn't be especially concerned about it. And I think the result might actually be favorable since it's a chance to talk over all these matters. Now over the longer term, as we've discussed many times, I believe tax differentials will be preserved because it's sensible for public health, it's sensible for the consumers. As we also covered, there's actually headroom for us to absorb taxes should differentials happen to narrow, since IQOS—partly to hand some of the tax advantage over to buyers—sits essentially at a mid-price point when you take the weighted average across countries, that's the first thing; and second, its price productivity far exceeds that of cigarettes, so when a tax gets passed through, the resulting price rise is smaller than what happens when tax is passed through on cigarettes; so that's basically how to think about it, though we do have to presume excise taxes will rise over time for RRPs too, given that governments require funds, and that will hit heated tobacco products, which are already heavily taxed, and possibly, in certain instances, e-vapor products down the road; but all of that is already factored into the assumptions.

Gaurav Jain

analyst
#25

Alright, and one final item from me — it concerns minority interest, which has been climbing faster than your EBIT does, and the Philippines is what's behind that. So could you lower that minority interest, given that your partner over in the Philippines trades on the exchanges at roughly 6x PE?

André Calantzopoulos

executive
#26

No, that's not something we envision. Not in the — well, should our partner ever wish to sell, we could talk about it. Right now, they're quite pleased with us.

Emmanuel Babeau

executive
#27

We're very happy with our partnership in Philippines.

Adam Spielman

analyst
#28

So, starting off, I believe during your guidance you mentioned that you expect to accept reduced pricing flexibility on combustible cigarettes compared to what's typical. For many, many years, that figure has stood at 6%, and I think you attributed wanting to take less pricing to something connected with COVID. That really caught me off guard. You also mentioned that the pricing model has been broken. So I guess my question is this: if you accept less pricing on combustibles during this year, 2021, what circumstances would need to arise for you to experience another low year in 2022? That's my first question.

André Calantzopoulos

executive
#29

Okay. To begin with, we never stated we would accept less pricing; wherever a pricing opportunity exists, we will take pricing, and in my view the model continues to function quite well. Elasticities remain unchanged, everything; we needed to make certain assumptions — reasonable, conservative, one might say — about what will occur in Indonesia and Russia resulting from the tax increase; and Indonesia has never received its carryover from the prior year, which renders year-over-year comparisons difficult, alright? On top of that, in Germany we had a VAT, let's call it a tax break, which we're assuming won't persist into this year; so once you strip out all those elements, I believe we're still looking at normal pricing across the other markets. So obviously, regarding post-COVID, let's say, assumptions, we need to monitor price gaps more closely, that's certain, at the mid- to low end of the market, though that doesn't imply we'll make any drastic pricing moves right now anywhere. It's just — this is something to watch out for. Should down trading occur, which is taking place between the mid-price typically and the low-price segment, partly due to the absence of contraband and all those factors, that's something to monitor in certain markets. But on the whole, I think we're in good shape. Additionally, for both IQOS, for heat-not-burn products and combustibles, excise taxes are now in place, if I recall correctly, everywhere; so we have fairly good visibility of our position, alright? So I don't believe it's heavily COVID related. What is COVID related within the guidance is the range we provided because if you examine, Adam, what occurred last year, assuming a 2% to 3% underlying industry decline, even factoring in Indonesia, we saw a 6.7% industry decline; so we're missing consumption mathematically of 3.7% to 4.7%. On average, that's $100 billion for the industry. So we don't — that will rebound, in my opinion, eventually, but only once the restrictions end. Now we provided guidance for this year of 0 to minus 3, which at 0, you get some recovery. At minus 3, you get super underlying negativity, perhaps exaggerated. I don't know at this point, but that's plus/minus 20 billion units for us. So that's plus/minus 2.5 revenue points. So that's where the volatility lies, alright? And should pricing improve in Russia and Indonesia, so much the better. We could land at the top of that range.

Adam Spielman

analyst
#30

Okay, that leads me into my next question. Honestly, the EPS guidance is confusing to me, and there are several parts of it I'd like to break down. First off, you're saying that during Q1 — even though the comparison is extremely tough — organic sales will be unchanged, margins will widen, and like-for-like EPS growth will come in at 8%. After that, you indicate that because the comparison becomes very easy in Q2, it's going to be a strong quarter — or at least that's the impression you're giving. Even so, across the entire year that amounts to just 9% to 11%. And from where I sit, if you can deliver results that strong in Q1 while having a weak Q2, then that 9% to 11% figure looks far too cautious. Let me frame the same point differently. Whenever you've put out EPS guidance at any point since 2018, you've been sandbagging. Take this quarter — what you provided wasn't a range but a single point estimate. You told us roughly $1.20 for Q4, and that was stated back in December, yet you ended up blowing past it by a wide margin. So that implies your method of issuing guidance is consistently, extraordinarily conservative. So one possibility is that you simply can't predict what's coming — which I doubt — and the other is that your approach is just wired to be extremely cautious. And on that, the fact that you've consistently kept pricing modest and still did so well in Q1 despite a very difficult comparison tells me the outlook you've given for the entire year is probably also very cautious. Would that be a reasonable read?

André Calantzopoulos

executive
#31

Cautious isn't the word I'd pick, though bullish wouldn't fit either, all right? I hear what you're getting at, but we're only just into the year, all right? A lot could still unfold with COVID since it hasn't gone away; as Emmanuel mentioned, we incurred over $150 million in exceptional costs last year tied to COVID, all right? You've got to leave a little room in the bottom line for costs you didn't see coming. And suppose things bounce back — and I wouldn't describe that as a slow, steady climb — then later in the year we might spend somewhat more to speed up acquisition. That's something you can actually go out and do. If it turns out we can't, well, then that cash clearly flows into the bottom line. So right now, that's the range we put out, and honestly, assuming the dollar holds at its current level, that's pretty solid, since it works out to 14% to 16%, with the revenue line coming in at 8% to 11%, which I'd call phenomenal. So I wouldn't label this conservative. The thing is, I can't predict what will occur in each month of this year — that's simply not possible. We aren't back to a standard state yet. That's really it. So I get it, and — but — I'm not sure what more I can say.

Emmanuel Babeau

executive
#32

Simply as part of the order of events, please take into account that — well, as we put it, we refer to a step-by-step rebound we anticipate while obviously being unable to map out precisely what the path will look like, yet that would certainly involve additional investment in H2. Keep in mind, naturally, our commercial activity has been constrained. As you're aware, we state that H2 might be a stronger period on the whole as various restrictions get relaxed. More investment will also be weighted toward the latter portion of the year. So that has to be factored in, and it also clarifies why Q1 perhaps is now viewed as better than what anyone might have anticipated at the outset. However, that investment has to take place within the year.

André Calantzopoulos

executive
#33

In any event, I'd prefer to err on the side of caution, and as the quarters go by, we'll receive additional information. However, I believe I've already outlined the boundaries. Regarding pricing, it could still turn out to be more advantageous. That flows directly down to the bottom line. Should we end up with a bit more combustible, that's acceptable. It lands on the bottom line, yet we need to factor that in. So as the quarters go on, we'll provide you with an improved outlook.

Robert Rampton

analyst
#34

What's the actual process for joining the queue?

Nick Rolli

executive
#35

Operator, please add Robert Rampton from UBS to the queue.

Nick Rolli

executive
#36

Robert, are you able to hop on? All right. Operator, we'll reconnect with Robert once this call wraps up. Let's move ahead to the closing comments, if that works. Andre, I believe you'd like to say a few words to wrap us up.

André Calantzopoulos

executive
#37

All right, and thanks, everyone, for being here. I'd say 2020 turned out to be quite a messy year, yet the outcome ended up far stronger than what I'd imagined back in March when we spoke for the very first time. In relative terms, I believe we're seeing a really solid rebound as we move through '21. IQOS keeps expanding at a robust pace. From where I sit, that momentum looks terrific, and hopefully we'll witness a bit of a bounce back in cigarette volumes over the coming 1 to 2 years. It would be great to see the total market turn positive perhaps in '22; and next week, in fact, we're eager to share more with all of you about long-term growth as well as more insight into how profitable IQOS is. So enjoy the rest of your day, and many thanks for tuning in to us.

Nick Rolli

executive
#38

Much appreciated. One more thing I'd like to mention — should anything else come up that you'd like to ask, feel free to reach out to the Investor Relations team, and our website has the details you'll need about signing in for the Investor Day event. The start time is 8:30 Eastern Time on February 10. Registration is available through our site; and once again, many thanks for being with us on this call. Enjoy the rest of your day.

Emmanuel Babeau

executive
#39

Bye.

Operator

operator
#40

That brings today's conference call to an end. We appreciate everyone taking part, and we ask that you please hang up your lines.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Philip Morris International Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Philip Morris International Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Philip Morris International Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.